These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 14643298)

  • 1. Drug transport and drug resistance in African trypanosomes.
    Mäser P; Lüscher A; Kaminsky R
    Drug Resist Updat; 2003 Oct; 6(5):281-90. PubMed ID: 14643298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of drug resistance in Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense. Treatment of human African trypanosomiasis with natural products (Review).
    Gehrig S; Efferth T
    Int J Mol Med; 2008 Oct; 22(4):411-9. PubMed ID: 18813846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotypic and phenotypic characterization of Trypanosoma brucei gambiense isolates from Ibba, South Sudan, an area of high melarsoprol treatment failure rate.
    Maina N; Maina KJ; Mäser P; Brun R
    Acta Trop; 2007; 104(2-3):84-90. PubMed ID: 17765860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aquaporin 2 mutations in Trypanosoma brucei gambiense field isolates correlate with decreased susceptibility to pentamidine and melarsoprol.
    Graf FE; Ludin P; Wenzler T; Kaiser M; Brun R; Pyana PP; Büscher P; de Koning HP; Horn D; Mäser P
    PLoS Negl Trop Dis; 2013; 7(10):e2475. PubMed ID: 24130910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapeutic strategies against Trypanosoma brucei: drug targets vs. drug targeting.
    Lüscher A; de Koning HP; Mäser P
    Curr Pharm Des; 2007; 13(6):555-67. PubMed ID: 17346174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target-based drug discovery for human African trypanosomiasis: selection of molecular target and chemical matter.
    Gilbert IH
    Parasitology; 2014 Jan; 141(1):28-36. PubMed ID: 23931634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The human trypanolytic factor: a drug shaped naturally.
    Vanhamme L
    Infect Disord Drug Targets; 2010 Aug; 10(4):266-82. PubMed ID: 20429865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, Trypanosoma brucei gambiense efficacy, and time of drug action of DB829, a preclinical candidate for treatment of second-stage human African trypanosomiasis.
    Wenzler T; Yang S; Braissant O; Boykin DW; Brun R; Wang MZ
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5330-43. PubMed ID: 23959303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Veterinary link to drug resistance in human African trypanosomiasis?
    Barrett MP
    Lancet; 2001 Aug; 358(9282):603-4. PubMed ID: 11530144
    [No Abstract]   [Full Text] [Related]  

  • 10. Melarsoprol sensitivity profile of Trypanosoma brucei gambiense isolates from cured and relapsed sleeping sickness patients from the Democratic Republic of the Congo.
    Pyana Pati P; Van Reet N; Mumba Ngoyi D; Ngay Lukusa I; Karhemere Bin Shamamba S; Büscher P
    PLoS Negl Trop Dis; 2014 Oct; 8(10):e3212. PubMed ID: 25275572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis.
    Nok AJ
    Parasitol Res; 2003 May; 90(1):71-9. PubMed ID: 12743807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The phenomenon of treatment failures in Human African Trypanosomiasis.
    Brun R; Schumacher R; Schmid C; Kunz C; Burri C
    Trop Med Int Health; 2001 Nov; 6(11):906-14. PubMed ID: 11703845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy of human African trypanosomiasis.
    Burchmore RJ; Ogbunude PO; Enanga B; Barrett MP
    Curr Pharm Des; 2002; 8(4):256-67. PubMed ID: 11860365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ever-increasing complexities of diamidine and arsenical crossresistance in African trypanosomes.
    de Koning HP
    Trends Parasitol; 2008 Aug; 24(8):345-9. PubMed ID: 18599351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
    Wenzler T; Boykin DW; Ismail MA; Hall JE; Tidwell RR; Brun R
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4185-92. PubMed ID: 19620327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative genomics of drug resistance in Trypanosoma brucei rhodesiense.
    Graf FE; Ludin P; Arquint C; Schmidt RS; Schaub N; Kunz Renggli C; Munday JC; Krezdorn J; Baker N; Horn D; Balmer O; Caccone A; de Koning HP; Mäser P
    Cell Mol Life Sci; 2016 Sep; 73(17):3387-400. PubMed ID: 26973180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diamidines for human African trypanosomiasis.
    Paine MF; Wang MZ; Generaux CN; Boykin DW; Wilson WD; De Koning HP; Olson CA; Pohlig G; Burri C; Brun R; Murilla GA; Thuita JK; Barrett MP; Tidwell RR
    Curr Opin Investig Drugs; 2010 Aug; 11(8):876-83. PubMed ID: 20721830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo evaluation of 28DAP010, a novel diamidine for treatment of second-stage African sleeping sickness.
    Wenzler T; Yang S; Patrick DA; Braissant O; Ismail MA; Tidwell RR; Boykin DW; Wang MZ; Brun R
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4452-63. PubMed ID: 24867978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aquaglyceroporin-null trypanosomes display glycerol transport defects and respiratory-inhibitor sensitivity.
    Jeacock L; Baker N; Wiedemar N; Mäser P; Horn D
    PLoS Pathog; 2017 Mar; 13(3):e1006307. PubMed ID: 28358927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and structure-activity relationships of new quinolone-type molecules against Trypanosoma brucei.
    Hiltensperger G; Jones NG; Niedermeier S; Stich A; Kaiser M; Jung J; Puhl S; Damme A; Braunschweig H; Meinel L; Engstler M; Holzgrabe U
    J Med Chem; 2012 Mar; 55(6):2538-48. PubMed ID: 22376072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.